Jazz pays $125m upfront for sleep drug

Jazz Pharmaceuticals has followed up its $1bn December acquisition of Italian company Gentium with a new agreement to buy rights to Aerial BioPharma's ADX-N05, a novel compound in clinical development for the treatment of excessive daytime sleepiness in patients with narcolepsy. Jazz is paying $125m upfront for the product.